AbbVie (NYSE:ABBV) Profitability Rank

: 10 (As of Jun. 2023)

View and export this data going back to 2012. Start your Free Trial

AbbVie has the Profitability Rank of 10. It has a higher profitability and may stay that way.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

AbbVie's Operating Margin % for the quarter that ended in Jun. 2023 was 34.57%. As of today, AbbVie's Piotroski F-Score is 7.

Competitive Comparison

For the Drug Manufacturers - General subindustry, AbbVie's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

AbbVie Profitability Rank Distribution

For the Drug Manufacturers industry and Healthcare sector, AbbVie's Profitability Rank distribution charts can be found below:

* The bar in red indicates where AbbVie's Profitability Rank falls into.

AbbVie Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

AbbVie has the Profitability Rank of 10. It has a higher profitability and may stay that way.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

AbbVie's Operating Margin % for the quarter that ended in Jun. 2023 is calculated as:

Operating Margin %	=	Operating Income (Q: Jun. 2023 )	/	Revenue (Q: Jun. 2023 )
	=	4793	/	13865
	=	34.57 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

AbbVie has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

Good Sign:

AbbVie Inc operating margin is expanding. Margin expansion is usually a good sign.

4. Consistency of the profitability

5. Predictability Rank

AbbVie Profitability Rank Related Terms

Thank you for viewing the detailed overview of AbbVie's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

AbbVie (NYSE:ABBV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AbbVie Inc (NYSE:ABBV) » Definitions » Profitability Rank

Comparable Companies

Traded in Other Exchanges

ABBV:Mexico 0QCV:UK 4AB:Germany ABBV:Canada ABBV34:Brazil ABBV:Austria

Address

1 North Waukegan Road, North Chicago, IL, USA, 60064-6400

Website

http://www.abbvieinvestor.com

AbbVie is a pharmaceutical firm with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

Executives

Kevin K Buckbee	officer: SVP, Controller	1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Perry C Siatis	officer: EVP, GC and Secretary	1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Scott T Reents	officer: SVP, Chief Financial Officer	1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Elaine K. Sorg	officer: Sr. V.P., U.S. Commercial Ops.	1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Carrie C Strom	officer: SVP & Pres Global Allerg Aesth	1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Edward J Rapp	director	100 NE ADAMS STREET, PEORIA IL 61629
Edward M Liddy	director	2775 SANDERS ROAD, NORTHBROOK IL 60062-6127
Robert J Alpern	director	YALE SCHOOL OF MEDICINE, 333 CEDAR STREET, C203 SHM, NEW HAVEN CT 06520
Timothy J. Richmond	officer: EVP, Chief HR Officer	1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Thomas J Hudson	officer: SVP, R&D and CSO	1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Nicholas Donoghoe	officer: SVP, Enterprise Innovation	1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Jeffrey Ryan Stewart	officer: SVP, US Commercial Operations	1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Brian L Durkin	officer: VP, Controller	1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Rebecca B Roberts	director	1000 LOUISIANA, SUITE 5800, HOUSTON TX 77002
Melody B Meyer	director	1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064